NMN for Non-Alcoholic Fatty Liver Disease: What the Evidence Actually Shows

By T Dinaiz · BSc Molecular Biology, MSc Biotechnology

Last reviewed 2026-04-28. NMN's evidence base, and Malaysian NPRA/JAKIM/price details, can change - confirm current status with primary sources and a registered doctor before acting.

Why NAFLD deserves a Malaysian-focused article

Non-alcoholic fatty liver disease (NAFLD) is now the most common liver disease in Malaysia and arguably the most underdiagnosed metabolic condition we have. It rides quietly on the back of our diabetes and obesity epidemic, often discovered by accident when a routine medical insurance ultrasound flags a “bright liver” or when ALT comes back twice the normal range during a pre-employment screen.

Patients then go online, find pages claiming NMN can fix fatty liver, and arrive at the supplement store without the necessary workup. This article tries to do better.

It explains what NAFLD actually is, what the Malaysian numbers look like, where NMN sits in the evidence (a smaller place than the marketing suggests), and how to integrate it responsibly with hepatologist follow-up if you decide it has a role.

What NAFLD actually is

NAFLD is the accumulation of triglyceride droplets in more than 5% of liver cells in the absence of significant alcohol intake. The condition exists on a clinical spectrum:

• NAFL (simple steatosis): fat without significant inflammation. Considered relatively benign, though not entirely without risk.
• NASH (non-alcoholic steatohepatitis): fat plus inflammation and ballooning of hepatocytes. Real driver of progression.
• Fibrosis (F1-F4): scarring as the liver tries to repair itself. F4 is cirrhosis.
• Cirrhosis: end-stage scarring, with all the complications that follow - portal hypertension, ascites, encephalopathy, variceal bleeding.
• Hepatocellular carcinoma (HCC): primary liver cancer, increasingly arising on a NAFLD background rather than viral hepatitis as Malaysia’s hepatitis C and B prevalence comes under control.

The terminology has been updated in recent international consensus. Many hepatologists now prefer MAFLD (metabolic-associated fatty liver disease) or MASLD (metabolic-associated steatotic liver disease) to emphasise the metabolic syndrome connection. ICD-10 still uses K76.0 for fatty liver, but you may see your hospital report using newer codes.

Malaysian prevalence: a bigger problem than most realise

The most-cited Malaysian estimate places NAFLD prevalence at roughly 22-30% of the general adult population. In subgroups it climbs sharply:

• Among Malaysian adults with obesity (BMI ≥ 27.5 by Asian cutoffs), NAFLD prevalence approaches 60-70%.
• Among patients with type 2 diabetes seen at Hospital Kuala Lumpur and UMMC, prevalence runs 50-65%.
• In children, paediatric NAFLD has been reported in 5-10% of overweight Malaysian schoolchildren, paralleling the rise in childhood obesity.

These numbers track our diabetes and metabolic syndrome epidemics. The NHMS surveys consistently show one in five Malaysian adults living with diabetes and roughly half of adults overweight or obese. NAFLD is the hepatic manifestation of that same metabolic dysfunction.

The Asian phenotype problem

Malaysian doctors increasingly recognise the “lean NAFLD” or “Asian phenotype” pattern. Asian populations develop visceral fat at lower BMI than European ones. A Malay or Chinese Malaysian patient at BMI 24 may have visceral adiposity, insulin resistance, and significant hepatic steatosis - features that a Western textbook would not flag until BMI 28 or 30.

This is why Malaysian guidelines and the Asian Pacific Association for the Study of the Liver (APASL) use BMI ≥ 23 as overweight and ≥ 27.5 as obese. If you have been told you are “not really overweight” because you are 70kg at 165cm but your liver enzymes are abnormal, the textbook your GP used may simply not fit your physiology.

How NAFLD develops: the metabolic syndrome connection

NAFLD does not arrive in isolation. It clusters with the rest of metabolic syndrome:

• Insulin resistance with raised fasting insulin
• Central obesity (waist circumference ≥ 90cm men, ≥ 80cm women using Asian cutoffs)
• Atherogenic dyslipidaemia (high triglycerides, low HDL, small dense LDL)
• Hypertension, often borderline at first
• Prediabetes or established type 2 diabetes

The hepatic story goes roughly like this. Insulin resistance pushes fatty acids into the liver. The liver cannot oxidise them fast enough through its mitochondria, so it esterifies them into triglyceride droplets.

Mitochondrial overload generates oxidative stress and reactive oxygen species. Inflammatory pathways activate, hepatic stellate cells lay down collagen, and over years to decades fibrosis appears.

Most readers will stay at NAFL forever. Roughly 20-30% progress to NASH, and a smaller subset to fibrosis or cirrhosis. The frustrating truth is that we cannot reliably predict who progresses. This is why monitoring matters even for “just fatty liver”.

NMN’s mechanism: where it might fit

NAD+ levels decline with age and metabolic stress. Gomes et al. (2013) showed that aged mice exhibit pseudohypoxic mitochondrial dysfunction driven by falling NAD+, and that restoring NAD+ rescues mitochondrial function. Cantó et al. (2012) demonstrated that NAD+ precursors enhance mitochondrial activity and oxidative metabolism.

For the liver, the relevant downstream players are:

• SIRT1, which deacetylates regulators of fatty acid oxidation, including PGC-1α. Active SIRT1 promotes mitochondrial biogenesis and lipid burning.
• SIRT3, which sits inside the mitochondrion itself and deacetylates enzymes of the beta-oxidation pathway. Active SIRT3 keeps the engine that disposes of fat in the liver running well.

Animal models of high-fat-diet-induced fatty liver show that boosting NAD+ through precursors like NMN or NR reduces hepatic steatosis, improves insulin signalling, and lowers inflammatory markers. Imai and Guarente’s 2014 review of the NAD+ field summarises this elegantly.

The mechanistic story is therefore plausible. The clinical story in humans is much smaller. Yoshino 2021 measured muscle insulin sensitivity, not liver fat. No published RCT has yet enrolled biopsy-proven or imaging-confirmed NAFLD patients on oral NMN with hepatic endpoints. NMN for NAFLD in 2026 is a promising hypothesis, not a proven therapy.

What actually works for NAFLD: the proven first line

If you have NAFLD, the interventions with the strongest evidence and largest effect sizes are unsexy but powerful:

Weight loss of 7-10% of body weight. This is the single most-studied intervention. At 5% loss, hepatic steatosis improves. At 7-10% loss, NASH activity scores improve and fibrosis can stabilise or even regress. For an 80kg adult, that is 6-8kg lost over 6-12 months - challenging but achievable.

Mediterranean-style eating. Olive oil, fish, nuts, legumes, whole grains, vegetables, modest fruit, limited red meat, minimal ultra-processed food. Adapted for Malaysian palates: think more ikan kembung and ikan tenggiri, more sayur ulam, brown rice over white when possible, tofu and tempeh, and a deliberate cut in roti canai, kuih-muih, and sweetened drinks. The evidence base for Mediterranean patterns specifically reducing hepatic fat is solid.

Aerobic and resistance exercise, 150 minutes per week of moderate activity. Even without weight loss, exercise reduces liver fat. Brisk walking around your taman, cycling, swimming at any local pool, and any form of strength training will help.

Treating co-morbidities. Optimise diabetes control, treat hypertension, manage dyslipidaemia. Statins are not contraindicated in NAFLD and are often appropriate.

No supplement, NMN included, has matched the effect size of these four pillars. Anything you add to NMN should sit on top of this foundation, not in place of it.

Baseline workup before starting NMN

Anyone with known or suspected NAFLD considering NMN should have a proper baseline. At minimum:

• Liver function tests: ALT, AST, ALP, GGT, bilirubin, albumin
• Full blood count and platelets (low platelets can suggest advanced fibrosis)
• Fasting glucose and HbA1c
• Lipid panel: LDL, HDL, triglycerides, total cholesterol
• Renal function: creatinine and eGFR
• Hepatitis B surface antigen and Hepatitis C antibody if not done in the past five years
• Imaging: ultrasound of the abdomen as a minimum; FibroScan if available, which gives a non-invasive read of liver stiffness (fibrosis) and CAP (steatosis)

A standard panel at a Klinik Kesihatan or private GP costs roughly RM150-RM350. FibroScan in private centres runs RM250-RM500. Document the baseline numbers so you have something to compare against at three and six months.

If your ALT is more than twice the upper limit of normal, or AST/ALT ratio > 1, or platelets are low, do not start any new supplement until a hepatologist has reviewed you. Acute or progressive liver disease has many causes - viral hepatitis, autoimmune hepatitis, drug-induced liver injury, Wilson’s disease in younger patients - and not all of them are NAFLD.

A cautious NMN discussion checklist for stable NAFLD patients

If your hepatologist has confirmed simple steatosis without significant inflammation or fibrosis, your enzymes are stable, and you are pursuing the lifestyle pillars seriously, the checklist below gives you a safer way to discuss NMN without turning it into a liver regimen.

Dose context to discuss: 250mg NMN once daily in the morning matches Yoshino 2021 and Igarashi 2022. Use this as a clinician discussion point, not a self-start instruction.

Duration of trial: 12 weeks before deciding whether to continue. Mechanistic effects, if present, will be small and slow.

Pairing: Ask before stacking TMG or any other supplement. Foundation supplements that may help - vitamin E 400 IU/day has limited NAFLD evidence (PIVENS trial), omega-3 1-2g/day, vitamin D if deficient. Discuss vitamin E specifically with your doctor as it has trade-offs.

Storage: Refrigerate the bottle between 4-8°C once opened. Tropical heat degrades NMN faster than label dates suggest.

Repeat tests at 12 weeks: ALT, AST, GGT, fasting glucose, lipid panel. If anything worsens, stop NMN and inform your doctor. If everything is stable or improved, you may continue, but plan the next review at six months.

Why purity matters more for fatty-liver patients

A compromised liver is less forgiving of contaminants. Adulterated supplements have been the source of multiple drug-induced liver injury (DILI) reports in Asian case series. NPRA Malaysia has issued repeated alerts on supplements adulterated with hidden corticosteroids, anabolic steroids, sibutramine, and unregistered actives - many of which are hepatotoxic.

For a patient who already has steatosis or mild fibrosis, the consequences of taking a contaminated capsule are higher than for a healthy adult. This makes purity verification non-negotiable:

• Insist on a certificate of analysis (COA) from an independent third-party laboratory, dated within the last 12-18 months.
• The COA should test for: purity (≥99% NMN), heavy metals (lead, mercury, cadmium, arsenic), residual solvents, and microbial limits.
• Verify the testing lab is independent, not a captive division of the brand.
• Avoid Instagram-only sellers without a Malaysian physical address or NPRA registration (MAL) number.
• Cross-check the brand against our directory and the latest NPRA alert list at npra.gov.my.

If a seller cannot produce a COA when asked, walk away. The few hundred ringgit you save is not worth a hepatic adverse event.

Drug interaction caveats

NAFLD patients often take other medications. Most commonly:

• Statins (atorvastatin, rosuvastatin, simvastatin). Hepatic metabolism, but generally safe to combine with NMN. Recheck enzymes at 12 weeks.
• Metformin. Compatible. Both target metabolic dysfunction through different mechanisms.
• SGLT2 inhibitors (empagliflozin, dapagliflozin) and GLP-1 agonists (semaglutide, liraglutide). Increasingly used in diabetic patients with NAFLD because they aid weight loss and may directly improve hepatic fat. No NMN-specific interaction data, but no theoretical concern.
• Vitamin E. PIVENS-trial supported in non-diabetic NASH at 800 IU/day. Some clinicians use it. Discuss separately with your hepatologist.
• Hepatic-cleared antiepileptics, antiretrovirals, antifungals. These warrant extra caution. Tell your specialist before you add NMN.
• Avoid stacking NMN with other “liver detox” supplements like silymarin (milk thistle), curcumin extracts, or unregulated TCM formulations without medical input. The liver does not need detoxing; it needs less work to do.

When to discontinue

Stop NMN and contact your doctor if:

• ALT or AST rises above 1.5x your baseline at any review
• Bilirubin rises or you develop jaundice (yellowing of skin or eyes)
• New right-upper-quadrant pain
• Dark urine or pale stools
• Severe fatigue, nausea, or anorexia
• You are admitted to hospital for any reason
• Within 14 days of any planned liver biopsy or surgery

Coordinating with Malaysian specialists

Most patients with newly diagnosed fatty liver in Malaysia are seen first by a GP or by an internal medicine clinic at a public hospital. Referral to a Pakar Hepatologi or Pakar Gastroenterologi happens when ALT runs persistently above 1.5x normal, when imaging suggests fibrosis, or when the patient has additional risk factors such as diabetes or a family history of cirrhosis.

Public hospital wait times for non-urgent cases run 6-12 weeks; private centres are faster but typically cost RM250-RM450 per consultation.

Bring three things to your appointment: your supplement bottles (NMN included), a list of any traditional remedies you take, and your most recent blood tests. Specialists routinely see patients who hide their supplement use, sometimes with serious consequences. Transparency makes their job easier and protects you.

If your hepatologist is unfamiliar with NMN, hand them a printed copy of the Yoshino 2021 abstract and the Rajman 2018 review - both are in PubMed and form a fair picture in 15 minutes of reading.

Halal context

NMN as a molecule is fermentation-derived from microbial precursors, which is acceptable to most JAKIM and recognised foreign halal authorities. The halal concern, as with most encapsulated supplements, is the capsule shell and excipients:

• HPMC (vegetable cellulose) capsules are universally accepted as halal.
• Bovine gelatin capsules require a halal certification confirming halal slaughter and proper sourcing.
• Porcine gelatin capsules are not acceptable for Muslim consumers.

For NAFLD patients who are Muslim, prefer HPMC-shell products with a JAKIM logo or one of the recognised foreign certifications (MUI Indonesia, JAKIM-recognised bodies in Australia, Singapore, Turkey, etc). Cross-check our halal directory for the current list.

Bottom line

NAFLD is common, often silent, and progressive in a meaningful subset of patients. Lifestyle change - weight loss, Mediterranean-style eating, exercise - is the only intervention with strong evidence for reversing the disease. NMN is an interesting mechanistic candidate that has not yet been tested in a proper human NAFLD trial.

If you decide to discuss it, do so with eyes open. Get a baseline panel. Bring the published trial-dose context to your clinician rather than self-starting from a webpage.

Buy only from a brand that can produce a lot-specific certificate of analysis. Repeat your bloods at the interval your doctor sets. Coordinate with a Pakar Hepatologi or Pakar Gastroenterologi if anything looks off.

Most of all, do not let a supplement bottle distract you from the harder, more effective work of changing what you eat, how much you move, and what number sits on your scale.